Dabur India Stock Price - ₹380.70 | Consumer Goods

‌
‌
‌

Company insights, generated from the most recent coverage.

Negligible operational impact from Nepal floods; no manufacturing facilities in Nepal, only distributor presence with robust alternative channels.
Read more
Segmented portfolio strategy targets premium products with 20% higher MRP and accretive gross margins across categories.
Read more
Using e-commerce as a launchpad for premium product introductions and leveraging sustainability trends for price premiums.
Read more

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Dabur rebounds strongly in Q1 FY27 with record revenue and restored margins after a soft Q4 FY26.

Consolidated revenue grew from ₹2,131.7 Cr to ₹2,687.3 Cr from Q4 FY26 to Q1 FY27, reversing the previous quarter's slowdown.

Material cost spiked from ₹1,172.1 Cr to ₹1,495.2 Cr from Q4 FY26 to Q1 FY27, reflecting higher input inflation.

Net profit rose from ₹295.6 Cr to ₹452.4 Cr from Q4 FY26 to Q1 FY27, restoring bottom-line strength.

Healthcare contribution fell from 37% to 24% from Q3 FY26 to Q1 FY27, shrinking its portfolio share.

Home & Personal Care revenue climbed from ₹1,008 Cr to ₹1,385 Cr from Q4 FY26 to Q1 FY27, driving core expansion.

Healthcare revenue dropped from ₹896 Cr to ₹623 Cr from Q3 FY26 to Q1 FY27, showing seasonal volatility.

EBITDA margin recovered from 21.8% to 24.8% from Q4 FY26 to Q1 FY27, showing stable pricing power.

Other expenses eased from ₹314 Cr to ₹268 Cr from Q4 FY26 to Q1 FY27, but remain above early FY26 levels.

Foods & Beverages revenue rebounded from ₹317 Cr to ₹528 Cr from Q3 FY26 to Q1 FY27, signaling strong category demand.

‌
‌
‌

In the news

Delhi High Court Stays FSSAI Ban on Dabur Product Over '100%' Claims

FMCG Pricing Strategies: Margin Protection vs Volume Growth

USFDA places Dabur under Import Alert 66-40 after Silvassa violations

Dabur's FSSAI Crisis: The Cost of "100%" Claims

Delhi HC Stays FSSAI Order Against Dabur India Until Next Hearing

Dabur India: Anand Rathi upgrades to buy, targets ₹550

Dabur Q1FY27 Results: Profit rises 15% YoY to ₹591 crore

Swiggy Gets Mixed Buy Ratings; Targets ₹350-₹520

Dabur India declares ₹5.50 final dividend, Q1FY27 shows double-digit growth

FMCG Q1 results: Strong growth expected amid margin resilience

Dabur Q1 outlook draws mixed brokerage response amid growth recovery

Dabur India falls for fifth straight session, down 0.44%

Dabur, HUL Implement Price Hikes and Pack Size Reductions

Govt tightens cough syrup rules, pharma stocks fall up to 1.11%

Dabur's FDA Import Alert: Quality Crisis at Silvassa

FMCG distributors threaten protest over shrinking margins, rising costs

FMCG Index Falls 2.36% as ITC Hits 52-Week Low on GST Hike Impact

Lupin shares in focus after USFDA EIR for Ankleshwar facility

FMCG Companies Shrink Rs 10 Packs as Rupee Hits Asia's Worst

Fuel price hike triggers economic concerns amid West Asia conflict

Dabur India